David Einhorn - DME Capital Management,
Holding/activity history for Gain Therapeutics Inc. (GANX)
| Period | Shares | % of Portfolio | Activity | % Change to Portfolio | Reported Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026 Q1 | 566,130 | 0.03 | $1.94 | $1,098,292 | SEC | ||
| 2025 Q4 | 566,130 | 0.06 | $3.22 | $1,822,939 | SEC | ||
| 2025 Q3 | 566,130 | 0.04 | $1.77 | $1,002,050 | SEC | ||
| 2025 Q2 | 566,130 | 0.04 | $1.80 | $1,019,034 | SEC | ||
| 2025 Q1 | 566,130 | 0.05 | $1.91 | $1,081,308 | SEC | ||
| 2024 Q4 | 566,130 | 0.06 | $2.16 | $1,222,841 | SEC | ||
| 2024 Q3 | 566,130 | 0.04 | $1.78 | $1,007,711 | SEC | ||
| 2024 Q2 | 566,130 | 0.04 | $1.28 | $724,646 | SEC | ||
| 2024 Q1 | 566,130 | 0.10 | $3.77 | $2,134,310 | SEC |